Treatment
Cell clinical trials
We’re tracking 5,691 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT04249830Recruiting
Donor stem cell transplant after donor cell targeting in youth
This trial studies a special donor stem cell transplant where the donor’s immune cells are reduced, aiming to lower harmful immune attacks after transplant. It may help children and young adults with certain high-risk blood cancers or rare bone marrow disorders.
Palo Alto, CaliforniaAges 1 month–60 years - NCT04300998Recruiting
CAR-T therapy study for older adults
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
New York, New YorkAges 60 years+ - NCT04332822RecruitingPhase 3
Testing mini-CHOP versus adding polatuzumab for lymphoma
This study compares two lymphoma treatments: mini-CHOP alone versus mini-CHOP plus a drug called polatuzumab vedotin. It aims to see which regimen works better and is tolerable for older or frail people with certain types of aggressive B-cell lymphoma.
AlburyAges 75 years+ - NCT04342429Recruiting
Proton radiation study for small cell lung cancer
This study looks at a type of radiation treatment using proton beams (IMPT) for small cell lung cancer. It may help assess whether this approach can safely deliver the planned radiation doses to the chest.
Atlanta, GeorgiaAges 18 years+ - NCT04422912RecruitingPhase 1/Phase 2
Cell therapy trial for active pemphigus vulgaris
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
Redwood City, CaliforniaAges 18 years+ - NCT04544592RecruitingPhase 1/Phase 2
CD19 CAR-T for children and young adults with B-cell blood cancers
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
Aurora, ColoradoAges 1 month–30 years - NCT04648046RecruitingPhase 1/Phase 2
CAR-T cell treatment for HIV infection
This early-phase study tests whether CAR-T cells (immune cells modified to recognize HIV) can help control HIV. You may be asked to briefly pause HIV medicines to see how well the treatment controls the virus.
Sacramento, CaliforniaAges 18–65 - NCT04762199RecruitingPhase 1
MRX-2843 with osimertinib for EGFR-mutant lung cancer
This Phase 1 study tests whether combining MRX-2843 with osimertinib can help control advanced lung cancer that has specific EGFR gene changes. It is designed to find the safest dose and check early signs of tumor response.
Atlanta, GeorgiaAges 18 years+ - NCT04774536RecruitingPhase 1/Phase 2
CRISPR gene-edited bone marrow transplant for severe sickle cell
This Phase 1/2 study tests a CRISPR-edited bone marrow (stem cell) transplant to treat severe sickle cell disease. It aims to reduce dangerous sickle-related complications by changing the patient’s stem cells before transplant.
Los Angeles, CaliforniaAges 12–35 - NCT04787042RecruitingPhase 1/Phase 2
Safety and early benefits of ST-067 for advanced solid tumors
This early-stage trial tests ST-067 to see if it is safe and whether it may shrink advanced cancers. It also looks at how the drug moves through the body and affects the immune system.
Scottsdale, ArizonaAges 18 years+ - NCT04790253Recruiting
Check brain radiation timing or frequent MRI scans for SCLC
This study compares two ways to follow and treat small-cell lung cancer in the brain: preventive brain radiation versus close monitoring with MRI scans and treatment only if needed. It may help people avoid unnecessary brain treatment or choose the safer timing strategy.
GrazAges 18 years+ - NCT04804007RecruitingPhase 2
Etoposide or watchful waiting after high-dose chemo
This phase 2 study looks at whether taking oral etoposide after high-dose chemotherapy helps people with a certain type of testicular or ovarian cancer avoid relapse. If you qualify, you may be assigned to take the medicine or simply be monitored without additional treatment.
Indianapolis, IndianaAges 18 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT04832607RecruitingPhase 3
Donor T-cell treatment for stubborn CMV, EBV, or Adenovirus after transplant
This Phase 3 trial tests giving special immune cells from your stem-cell donor to treat difficult-to-control viral infections after a stem cell transplant. It may help your body fight the virus when standard antiviral medicines haven’t worked well enough.
BrusselsAges 2 months+ - NCT04892849Recruiting
PD-1/PD-L1 immunotherapy plus radiation for solid tumors
This study tests whether combining an immune system medicine (PD-1/PD-L1 inhibitor) with radiation can improve outcomes in people with certain solid cancers. It also looks for blood or tissue “biomarkers” that may explain who benefits most.
Erlangen, BavariaAges 18 years+ - NCT04892953RecruitingPhase 2
Durvalumab plus focused radiation for progressing stage III lung cancer
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
Houston, TexasAges 18 years+ - NCT04894370RecruitingPhase 2
Trial tests immunotherapy plus chemotherapy and radiation for anal cancer
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
BesançonAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT04919629RecruitingPhase 2
Tested treatments for recurrent ovarian cancer with fluid buildup
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
Buffalo, New YorkAges 18 years+ - NCT04920617RecruitingPhase 2
Vaccine plus pembrolizumab, with or without low-dose chemo
This Phase 2 study tests whether a cancer vaccine called DPX-Survivac, along with pembrolizumab (an immune medicine), can help shrink diffuse large B-cell lymphoma (DLBCL) that has come back or not responded. It also looks at whether adding intermittent low-dose cyclophosphamide (a low-dose chemotherapy) improves results.
Fountain Valley, CaliforniaAges 18 years+ - NCT05735717RecruitingPhase 2
T-cell transplant using depleted receptors for blood cancers
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT06742996RecruitingPhase 3
Sonrotoclax plus zanubrutinib for relapsed mantle cell lymphoma
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
Birmingham, AlabamaAges 18 years+ - NCT07599176RecruitingPhase 1/Phase 2
Partial stem cell transplant for sickle cell disease from matched donors
This study tests a partial stem cell transplant from a matched donor to treat sickle cell disease. It may help reduce complications like strokes, organ damage, or pain crises.
Bethesda, MarylandAges 4–65
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,691 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.